Switch theme
Sign up to access all valuation multiples
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited or no treatment options. The Company’s current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company’s commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
2017
57
LTM Revenue $8.0M
Last FY EBITDA -$14.4M
$101M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alpha Cognition has a last 12-month revenue (LTM) of $8.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Alpha Cognition achieved revenue of n/a and an EBITDA of -$14.4M.
Alpha Cognition expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alpha Cognition valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$14.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$19.4M | XXX | -$10.9M | XXX | XXX | XXX |
| EBIT Margin | -242% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$19.4M | XXX | -$14.6M | XXX | XXX | XXX |
| Net Margin | -242% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Alpha Cognition's stock price is $9.
Alpha Cognition has current market cap of $149M, and EV of $101M.
See Alpha Cognition trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $101M | $149M | XXX | XXX | XXX | XXX | $-1.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Alpha Cognition has market cap of $149M and EV of $101M.
Alpha Cognition's trades at n/a EV/Revenue multiple, and -7.0x EV/EBITDA.
Equity research analysts estimate Alpha Cognition's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alpha Cognition has a P/E ratio of -7.7x.
See valuation multiples for Alpha Cognition and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $149M | XXX | $149M | XXX | XXX | XXX |
| EV (current) | $101M | XXX | $101M | XXX | XXX | XXX |
| EV/Revenue | 12.6x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -7.0x | XXX | XXX | XXX |
| EV/EBIT | -5.2x | XXX | -9.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.7x | XXX | -10.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -13.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlpha Cognition's last 12 month revenue growth is 222%
Alpha Cognition's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.2M for the same period.
Alpha Cognition's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alpha Cognition's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alpha Cognition and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 222% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Race Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Aclaris Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alpha Cognition acquired XXX companies to date.
Last acquisition by Alpha Cognition was XXXXXXXX, XXXXX XXXXX XXXXXX . Alpha Cognition acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alpha Cognition founded? | Alpha Cognition was founded in 2017. |
| Where is Alpha Cognition headquartered? | Alpha Cognition is headquartered in United States of America. |
| How many employees does Alpha Cognition have? | As of today, Alpha Cognition has 57 employees. |
| Who is the CEO of Alpha Cognition? | Alpha Cognition's CEO is Mr. Michael McFadden. |
| Is Alpha Cognition publicy listed? | Yes, Alpha Cognition is a public company listed on NAS. |
| What is the stock symbol of Alpha Cognition? | Alpha Cognition trades under ACOG ticker. |
| When did Alpha Cognition go public? | Alpha Cognition went public in 2021. |
| Who are competitors of Alpha Cognition? | Similar companies to Alpha Cognition include e.g. Race Oncology, Supriya Lifescience, Ascentage Pharma Group, ST Pharm. |
| What is the current market cap of Alpha Cognition? | Alpha Cognition's current market cap is $149M |
| What is the current revenue of Alpha Cognition? | Alpha Cognition's last 12 months revenue is $8.0M. |
| What is the current revenue growth of Alpha Cognition? | Alpha Cognition revenue growth (NTM/LTM) is 222%. |
| What is the current EV/Revenue multiple of Alpha Cognition? | Current revenue multiple of Alpha Cognition is 12.6x. |
| Is Alpha Cognition profitable? | Yes, Alpha Cognition is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
